Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Target Raised at HC Wainwright

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price target upped by equities research analysts at HC Wainwright from $88.00 to $106.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright‘s price objective would suggest a potential upside of 45.93% from the company’s previous close.

A number of other brokerages have also commented on TARS. Zacks Research raised Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 13th. The Goldman Sachs Group began coverage on Tarsus Pharmaceuticals in a report on Thursday, September 24th. They set a “buy” rating and a $116.00 price objective for the company. Barclays started coverage on Tarsus Pharmaceuticals in a report on Wednesday, September 16th. They set an “overweight” rating and a $110.00 price objective for the company. Mizuho cut their target price on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Finally, Oppenheimer lifted their price objective on shares of Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Tarsus Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $103.43.

Tarsus Pharmaceuticals Trading Down 0.9%

NASDAQ:TARS opened at $72.64 on Wednesday. The firm’s fifty day moving average is $75.17 and its 200-day moving average is $67.87. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.17 and a current ratio of 3.20. Tarsus Pharmaceuticals has a 52 week low of $53.89 and a 52 week high of $91.53. The firm has a market cap of $3.58 billion, a P/E ratio of -66.64 and a beta of 0.34.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Tuesday, November 3rd. The company reported ($14.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.46) by ($12.94). The firm had revenue of $194.57 million for the quarter, compared to the consensus estimate of $187.83 million. Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%. Equities analysts expect that Tarsus Pharmaceuticals will post -2.23 earnings per share for the current year.

Insider Buying and Selling

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 10,000 shares of the stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $90.56, for a total transaction of $905,600.00. Following the completion of the transaction, the chief executive officer owned 827,991 shares in the company, valued at $74,982,864.96. This trade represents a 1.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Lin sold 3,180 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $87.50, for a total transaction of $278,250.00. Following the completion of the transaction, the insider owned 1,590 shares of the company’s stock, valued at $139,125. This represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 48,031 shares of company stock valued at $4,004,227. 9.64% of the stock is owned by company insiders.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Large investors have recently modified their holdings of the company. Parallel Advisors LLC boosted its holdings in Tarsus Pharmaceuticals by 139.2% in the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock valued at $35,000 after purchasing an additional 291 shares during the period. Farther Finance Advisors LLC boosted its stake in Tarsus Pharmaceuticals by 851.6% in the third quarter. Farther Finance Advisors LLC now owns 590 shares of the company’s stock worth $46,000 after buying an additional 528 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Tarsus Pharmaceuticals by 367.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 710 shares of the company’s stock valued at $50,000 after purchasing an additional 558 shares during the last quarter. Covestor Ltd grew its position in Tarsus Pharmaceuticals by 40.0% during the 3rd quarter. Covestor Ltd now owns 1,095 shares of the company’s stock worth $86,000 after acquiring an additional 313 shares during the last quarter. Finally, Rockefeller Capital Management L.P. increased its stake in shares of Tarsus Pharmaceuticals by 15.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock worth $105,000 after buying an additional 172 shares during the period. 90.01% of the stock is currently owned by institutional investors.

Key Stories Impacting Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Q3 revenue rose about 64% year over year to $194.6 million, exceeding analyst estimates of $187.8 million. XDEMVY surpassed one million bottles dispensed and $1 billion in cumulative sales since launch. Tarsus Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Management expects XDEMVY sales of $715 million to $730 million in 2026, signaling continued confidence in the drug’s commercial opportunity. Tarsus expects $715M-$730M 2026 XDEMVY sales
• Positive Sentiment: Tarsus’s quarterly loss per share was $0.78, narrower than the $1.43 loss analysts expected, though the loss was larger than a year earlier. Tarsus Pharmaceuticals Reports Q3 Loss, Tops Revenue Estimates
• Negative Sentiment: The company is deferring regulatory filings in Europe and Japan, which could push back its international expansion and potential contribution to sales. Tarsus expects $715M-$730M 2026 XDEMVY sales while deferring Europe and Japan filings

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye diseases with significant unmet medical needs. The company’s portfolio is centered on therapies designed to address conditions affecting the ocular surface and eyelids.

Tarsus’ lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, an inflammatory eyelid condition associated with an infestation of Demodex mites.